We’re bringing innovation to the eye care space with integrin-regulating therapy, a new class of drugs for the treatment of ocular diseases.
Risuteganib (Luminate®), our primary investigational compound, is leading the charge with a novel mechanism of action that regulates multiple pathways of oxidative stress response, including mitochondrial dysfunction, which contribute to diseases such as intermediate non-exudative
ag...
We’re bringing innovation to the eye care space with integrin-regulating therapy, a new class of drugs for the treatment of ocular diseases.
Risuteganib (Luminate®), our primary investigational compound, is leading the charge with a novel mechanism of action that regulates multiple pathways of oxidative stress response, including mitochondrial dysfunction, which contribute to diseases such as intermediate non-exudative
age-related macular degeneration (intermediate dry AMD) and diabetic macular edema (DME).
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.